Neuren Pharmaceuticals (ASX:NEU) has received Fast Track designation from the US Food and Drug Administration for its investigational therapy NNZ-2591 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder with no approved therapies. …
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 Australian BiotechLatest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News